Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

被引：0

作者：

Enrique Grande

Michael C. Kreissl

Sebastiano Filetti

Kate Newbold

Walter Reinisch

Caroline Robert

Martin Schlumberger

Lærke K. Tolstrup

Jose L. Zamorano

Jaume Capdevila

机构：

[1] Hospital Ramón y Cajal,Servicio de Oncología Médica

[2] University Hospital of Wuerzburg,Department of Nuclear Medicine

[3] Central Hospital of Augsburg,Department of Nuclear Medicine

[4] University of Rome “Sapienza”,Department of Internal Medicine and Medical Specialities

[5] Royal Marsden Hospital,Thyroid Unit

[6] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III

[7] University of Paris-Sud,Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute

[8] University of Paris-Sud,Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute

[9] Odense University Hospital,Department of Oncology, Clinical Research Unit

[10] Hospital Ramón y Cajal,Cardiology Service

[11] Vall d’Hebron University Hospital,Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit

[12] Autonomous University of Barcelona,undefined

来源：

Advances in Therapy | 2013年 / 30卷

关键词：

Adverse effects; Antineoplastic agents/adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines/therapeutic use; Protein kinase inhibitors; Thyroid neoplasms/drug therapy; Vandetanib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：945 / 966

页数：21

共 50 条

[1] Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Grande, Enrique
Kreissl, Michael C.
Filetti, Sebastiano
Newbold, Kate
Reinisch, Walter
Robert, Caroline
Schlumberger, Martin
Tolstrup, Laerke K.
Zamorano, Jose L.
Capdevila, Jaume
ADVANCES IN THERAPY, 2013, 30 (11) : 945 - 966
[2] Vandetanib and the management of advanced medullary thyroid cancer
Campbell, Michael J.
Seib, Carolyn D.
Gosnell, Jessica
CURRENT OPINION IN ONCOLOGY, 2013, 25 (01) : 39 - 43
[3] Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer
Duplomb, Sophie
Benoit, Amandine
Mechtouff-Cimarelli, Laura
Cho, Tae-Hee
Derbel, Olfa
Peix, Jean Louis
de la Fouchardiere, Christelle
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : E21 - E23
[4] Role of vandetanib in the management of medullary thyroid cancer
Brassard, Maryse
Rondeau, Genevieve
BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 59 - 66
[5] Vandetanib In Medullary Thyroid Cancer
Frampton, James E.
DRUGS, 2012, 72 (10) : 1423 - 1436
[6] Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
Kim, Mijin
Yoon, Jee Hee
Ahn, Jonghwa
Jeon, Min Ji
Kim, Hee Kyung
Lim, Dong Jun
Kang, Ho-Cheol
Kim, In Joo
Shong, Young Kee
Kim, Tae Yong
Kim, Bo Hyun
ENDOCRINOLOGY AND METABOLISM, 2020, 35 (03) : 587 - 594
[7] Vandetanib—a new therapeutic option in advanced medullary thyroid cancer
Linda Koch
Nature Reviews Endocrinology, 2012, 8 (1) : 1 - 1
[8] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
Keating, Gillian M.
Lyseng-Williamson, Katherine A.
Frampton, James E.
BIODRUGS, 2012, 26 (06) : 431 - 435
[9] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
Gillian M. Keating
Katherine A. Lyseng-Williamson
James E. Frampton
BioDrugs, 2012, 26 (6) : 431 - 435
[10] Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas
Chougnet, Cecile N.
Schlumberger, Martin
Leboulleux, Sophie
Baudin, Eric
BULLETIN DU CANCER, 2014, 101 (09) : 891 - 895

← 1 2 3 4 5 →